Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
137 stopped studies mapped to Lymphoma by Site and descendants · 82% state a reason
Over the 137 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT07098364 | ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in… | Phase 1 / Phase 2 | suspended | Aug 1, 2025 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT07388563 | Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma | Phase 1 | suspended | Feb 5, 2026 | National Cancer Institute (NCI) | New recruitment on hold for a protocol design amendment/modification. | Enrollment / accrual |
| NCT02702310 | Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed… | — | suspended | Mar 8, 2016 | Vanderbilt-Ingram Cancer Center | Treatment unavailable at facility | Other (stated, no rule matched) |
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of… | Phase 1 | suspended | May 17, 2022 | Washington University School of Medicine | Drugs/Equipment Unavailable | Other (stated, no rule matched) |
| NCT06470451 | Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL(FLASH2) | Phase 3 | terminated | Jun 24, 2024 | Soligenix | The Data Monitoring Committee conducted an interim analysis and recommended that the study be… | Efficacy / futility |
| NCT06922604 | Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System… | Phase 1 | suspended | Apr 10, 2025 | City of Hope Medical Center | Pending Amendment Approval | Other (stated, no rule matched) |
| NCT05414500 | Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides | Phase 1 | suspended | Jun 10, 2022 | University of Alabama at Birmingham | IRB audit | Other (stated, no rule matched) |
| NCT02943642 | Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With…(Resimmune®) | Phase 2 | withdrawn | Oct 25, 2016 | Virogen Biotechnology Inc. | This record is an earlier version (crossover design). After FDA-approved IND sponsor transfer to… | Other (stated, no rule matched) |
| NCT06692452 | Tazemetostat Plus CHOP in 1L T-cell Lymphoma | Phase 2 | withdrawn | Nov 18, 2024 | Eric Jacobsen, MD | Ipsen requested a temporary closure due to a safety concern. | Safety / toxicity |
| NCT06235281 | Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)(PLIGHT) | Early Phase 1 | suspended | Jan 31, 2024 | H. Lee Moffitt Cancer Center and Research Institute | Slow Accrual | Enrollment / accrual |
| NCT04541017 | Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual… | Phase 1 / Phase 2 | terminated | Sep 9, 2020 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT05222269 | [68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients | Phase 2 | terminated | Feb 3, 2022 | Pentixapharm AG | The study was early terminated due to low patient recruitment in already activated sites and… | Enrollment / accrual |
| NCT05879458 | Ritlecitinib in CTCL | Phase 2 | terminated | May 30, 2023 | Icahn School of Medicine at Mount Sinai | No significant improvement in disease as graded by our assessments. | Other (stated, no rule matched) |
| NCT05538988 | BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd…(BIOSELECT) | Phase 1 / Phase 2 | withdrawn | Sep 14, 2022 | AHS Cancer Control Alberta | Contractual Issues | Other (stated, no rule matched) |
| NCT04735471 | A Phase 1 Study of ADI-001 in B Cell Malignancies(GLEAN-1) | Phase 1 | terminated | Feb 3, 2021 | Adicet Therapeutics | Terminated - Halted Prematurely | Other (stated, no rule matched) |
| NCT05106192 | Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel… | N/A | withdrawn | Nov 3, 2021 | Case Comprehensive Cancer Center | Study closed prior to enrollment of first participant | Enrollment / accrual |
| NCT03432741 | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With… | Phase 1 | terminated | Feb 14, 2018 | Mayo Clinic | funding - sponsor filing Chapter 11 bankruptcy | Funding |
| NCT02548468 | Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in… | Phase 1 | withdrawn | Sep 14, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT03288818 | Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel… | Phase 2 | withdrawn | Sep 20, 2017 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Funding discontinued | Funding |
| NCT04358458 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell… | Phase 1 / Phase 2 | terminated | Apr 24, 2020 | Genmab | Due to strategic evaluation of GEN3009 within context of Genmab's portfolio, decision not based on… | Safety / toxicity |
| NCT06625359 | High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by… | Phase 2 | terminated | Oct 3, 2024 | Seoul National University Hospital | slow enrollment | Enrollment / accrual |
| NCT04676087 | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or… | Phase 1 / Phase 2 | terminated | Dec 19, 2020 | Emory University | Lack of funding | Funding |
| NCT04806035 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell… | Phase 1 | terminated | Mar 19, 2021 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT03789864 | Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis…(BDI) | N/A | terminated | Dec 31, 2018 | Indiana University | Lack of accrual in a timely fashion | Enrollment / accrual |
| NCT03103971 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell… | Phase 1 | terminated | Apr 7, 2017 | Fred Hutchinson Cancer Center | Terminated due to slow enrollment and end of funding | Enrollment / accrual |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | Phase 1 | terminated | Jan 16, 2013 | Stanford University | Planned Future Study | Other (stated, no rule matched) |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT05138458 | A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL(IMAGINE) | Phase 1 / Phase 2 | suspended | Dec 1, 2021 | Myeloid Therapeutics | Temporary operational pause; no safety concerns. | Safety / toxicity |
| NCT04795869 | Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral… | Phase 2 | withdrawn | Mar 12, 2021 | Northwestern University | Study inactivated due to zero accruals | Enrollment / accrual |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant… | Phase 2 | terminated | Jan 8, 2010 | University of Nebraska | Study was closed to accrual for safety related to the frequency of BK infections. | Safety / toxicity |
| NCT05242146 | GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma(STAR CNS) | Phase 1 | terminated | Feb 16, 2022 | GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Sponsor decision | Sponsor / business decision |
| NCT01579318 | Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma(CTCL) | Phase 2 | terminated | Apr 17, 2012 | OncoSec Medical Incorporated | Due to company resource constraints | Sponsor / business decision |
| NCT03999658 | A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected… | Phase 2 | withdrawn | Jun 27, 2019 | Sorrento Therapeutics, Inc. | Sorrento Therapeutics filed for chapter 11 bankruptcy. | Other (stated, no rule matched) |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory… | Phase 1 | terminated | Sep 7, 2016 | Pfizer | not stated | Not stated |
| NCT04021082 | CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory… | Phase 2 / Phase 3 | withdrawn | Jul 16, 2019 | Portola Pharmaceuticals | Sponsor decision to not initiate the trial | Sponsor / business decision |
| NCT02314247 | Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell… | Phase 2 | terminated | Dec 11, 2014 | Karyopharm Therapeutics Inc | Due to enrollment challenges | Enrollment / accrual |
| NCT05228249 | Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for… | Phase 1 | withdrawn | Feb 8, 2022 | Fred Hutchinson Cancer Center | PI left institution and funding sponsor closed study. Study did not open to accrual, and no… | Investigator |
| NCT04639843 | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell… | Phase 1 | withdrawn | Nov 23, 2020 | National Cancer Institute (NCI) | Safety issues with PI3 kinase inhibitors | Safety / toxicity |
| NCT02811783 | Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of… | Phase 3 | terminated | Jun 23, 2016 | Elorac, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04635683 | Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory… | Phase 1 | withdrawn | Nov 19, 2020 | Yazeed Sawalha | Investigational Drug removed from the market | Other (stated, no rule matched) |
| NCT05156229 | A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).(Part B) | Phase 1 | terminated | Dec 14, 2021 | Codiak BioSciences | PK/PD from two patients plus the healthy volunteer data confirmed the RP2D and manageable safety… | Safety / toxicity |
| NCT02706405 | JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell… | Phase 1 | terminated | Mar 11, 2016 | Fred Hutchinson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT03704714 | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell… | Phase 1 / Phase 2 | suspended | Oct 15, 2018 | Northwestern University | Protocol being amended for stats/accrual changes as per PI | Enrollment / accrual |
| NCT04836832 | Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin… | Phase 1 | withdrawn | Apr 8, 2021 | Narendranath Epperla | PI decision | Other (stated, no rule matched) |
| NCT04844086 | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies | Phase 1 | terminated | Apr 14, 2021 | Eden BioCell Ltd. | CAR-T manufacturing technology can not meet the dose requirement for clinical patients. | Drug supply |
| NCT03713320 | SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With…(SOLAR) | Phase 2 | terminated | Oct 19, 2018 | miRagen Therapeutics, Inc. | The study was terminated early for business reasons, and not due to concerns regarding safety or… | Safety / toxicity |
| NCT02420795 | Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's… | Phase 1 / Phase 2 | terminated | Apr 20, 2015 | M.D. Anderson Cancer Center | Per PI Request | Other (stated, no rule matched) |
| NCT04073147 | Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma(VENOBI-CNS) | Phase 1 | terminated | Aug 29, 2019 | Klinikum Stuttgart | low recruitment | Enrollment / accrual |
| NCT02323659 | Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous… | Phase 4 | terminated | Dec 23, 2014 | Polish Lymphoma Research Group | Slow recruitment | Enrollment / accrual |
| NCT00476554 | A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous… | Phase 2 | terminated | May 22, 2007 | Cyclacel Pharmaceuticals, Inc. | slow accrual and financial resource limitation | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 18 days agoSource updated Sep 11, 2026source: clinicaltrials